Asset Details
Do you wish to reserve the book?
Cholesterol lowering and inhibition of sterol absorption by Lactobacillus reuteri NCIMB 30242: a randomized controlled trial
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Cholesterol lowering and inhibition of sterol absorption by Lactobacillus reuteri NCIMB 30242: a randomized controlled trial
Do you wish to request the book?
Cholesterol lowering and inhibition of sterol absorption by Lactobacillus reuteri NCIMB 30242: a randomized controlled trial
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Cholesterol lowering and inhibition of sterol absorption by Lactobacillus reuteri NCIMB 30242: a randomized controlled trial
2012
Overview
Background/Objectives:
The percentage of hypercholesterolemic individuals not reaching their LDL-cholesterol (LDL-C) goal remains high and additional therapeutic strategies should be evaluated. The objective of this study was to evaluate the cholesterol-lowering efficacy and mechanism of action of bile salt hydrolase-active
Lactobacillus reuteri
NCIMB 30242 capsules in hypercholesterolemic adults.
Subjects/Methods:
A total of 127 subjects completed a randomized, double-blind, placebo-controlled, parallel-arm, multicenter study. Subjects were randomized to consume
L. reuteri
NCIMB 30242 capsules or placebo capsules over a 9-week intervention period. The primary outcome was LDL-C relative to placebo at the study end point.
Results:
L. reuteri
NCIMB 30242 capsules reduced LDL-C by 11.64% (
P
<0.001), total cholesterol by 9.14%, (
P
<0.001), non-HDL-cholesterol (non-HDL-C) by 11.30% (
P
<0.001) and apoB-100 by 8.41% (
P
=0.002) relative to placebo. The ratios of LDL-C/HDL-cholesterol (HDL-C) and apoB-100/apoA-1 were reduced by 13.39% (
P
=0.006) and 9.00% (
P
=0.026), respectively, relative to placebo. Triglycerides and HDL-C were unchanged. High-sensitivity C-reactive protein and fibrinogen were reduced by 1.05 mg/l (
P
=0.005) and 14.25% (
P
=0.004) relative to placebo, respectively. Mean plasma deconjugated bile acids were increased by 1.00 nmol/l (
P
=0.025) relative to placebo, whereas plasma campesterol, sitosterol and stigmasterol were decreased by 41.5%, 34.2% and 40.7%, respectively.
Conclusions:
The present results suggest that the deconjugation of intraluminal bile acids results in reduced absorption of non-cholesterol sterols and indicate that
L. reuteri
NCIMB 30242 capsules may be useful as an adjunctive therapy for treating hypercholesterolemia.
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
/ Adult
/ Apolipoprotein B-100 - blood
/ Bile Acids and Salts - blood
/ Biological and medical sciences
/ C-Reactive Protein - metabolism
/ Cholesterol - analogs & derivatives
/ Female
/ Fundamental and applied biological sciences. Psychology
/ Heart
/ Humans
/ Hypercholesterolemia - blood
/ Hypercholesterolemia - drug therapy
/ Male
/ Medicine
/ Placebos
/ Sterols
/ Vertebrates: anatomy and physiology, studies on body, several organs or systems
